{"id":"ixiaro-japanese-encephalitis-vaccine","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Injection site pain, erythema, or swelling"},{"rate":"5–15%","effect":"Headache"},{"rate":"5–15%","effect":"Myalgia"},{"rate":"1–5%","effect":"Fever"},{"rate":"5–10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL6068364","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) Japanese encephalitis virus particles that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes viral antigens and develops protective immunity, enabling recognition and neutralization of live virus if exposure occurs. This provides protection against infection with Japanese encephalitis virus, which is transmitted by Culex mosquitoes in endemic regions of Asia and the Western Pacific.","oneSentence":"IXIARO is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:35.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in travelers and residents of endemic areas in Asia and the Western Pacific"}]},"trialDetails":[{"nctId":"NCT06680128","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2025-02-24","conditions":"Japanese Encephalitis Virus Disease","enrollment":402},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT01041573","phase":"PHASE3","title":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-03","conditions":"Encephalitis","enrollment":1869},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT01246479","phase":"PHASE3","title":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-10","conditions":"Japanese Encephalitis","enrollment":23},{"nctId":"NCT03971058","phase":"PHASE4","title":"Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2019-03-01","conditions":"Japanese Encephalitis Vaccine","enrollment":64},{"nctId":"NCT00740155","phase":"PHASE2","title":"Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":154},{"nctId":"NCT01296360","phase":"PHASE3","title":"Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Japanese Encephalitis","enrollment":300},{"nctId":"NCT00314145","phase":"PHASE3","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Japanese Encephalitis","enrollment":820},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT01158599","phase":"PHASE4","title":"This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-06","conditions":"Japanese Encephalitis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IXIARO®- Japanese Encephalitis vaccine","genericName":"IXIARO®- Japanese Encephalitis vaccine","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Biologic","firstApprovalDate":"","aiSummary":"IXIARO is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in travelers and residents of endemic areas in Asia and the Western Pacific.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}